Shingles News and Research RSS Feed - Shingles News and Research

Shingles (herpes zoster) is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chickenpox — the varicella-zoster virus. The first sign of shingles is often burning or tingling pain, or sometimes numbness or itch, in one particular location on only one side of the body.
Study finds decrease in Google searches for chickenpox after vaccination implementation

Study finds decrease in Google searches for chickenpox after vaccination implementation

Countries that implement government-mandated vaccinations for chickenpox see a sharp drop in the number of Google searches for the common childhood disease afterward, demonstrating that immunization significantly reduces seasonal outbreaks. [More]
Taking pregabalin drug during pregnancy could lead to major birth defects

Taking pregabalin drug during pregnancy could lead to major birth defects

A drug commonly used to treat pain, epilepsy, anxiety and other brain health disorders may be associated with an increased risk of major birth defects, according to a study published in the May 18, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Non-invasive optogenetic therapy can help treat chronic pain

Non-invasive optogenetic therapy can help treat chronic pain

The potential of light as a non-invasive, highly-focused alternative to pain medication was made more apparent thanks to research conducted by scientists at the Montreal Neurological Institute and Hospital of McGill University and the McGill University Health Centre. [More]
Heart failure drug has unexpected ability to block herpesvirus infection

Heart failure drug has unexpected ability to block herpesvirus infection

Today, there is only one class of antiviral medicines against herpesviruses - a family of viruses that cause mononucleosis, herpes, and shingles, among other illnesses - meaning options for treating these infections are limited. If viruses become resistant to these frontline treatments, a growing problem particularly in clinical settings, there are no alternative drugs to serve as backup. [More]
Researchers report first case of acute myelitis due to Zika virus infection

Researchers report first case of acute myelitis due to Zika virus infection

A first case of acute myelitis following infection with Zika virus has been reported for the first time by a research team from Inserm Unit 1127 Brain and Spinal Cord Institute (Inserm/CNRS/Sorbonne University) and neurologists at Pointe-à-Pitre University Hospital and the University of the Antilles. [More]
Electronic health records could help identify people who have undiagnosed type 2 diabetes

Electronic health records could help identify people who have undiagnosed type 2 diabetes

In 2012, a group of UCLA researchers set out to mine thousands of electronic health records for a more accurate and less expensive way to identify people who have undiagnosed type 2 diabetes. The researchers got much more than they bargained for. [More]
MU School of Medicine researchers find link between varicella zoster virus vaccine and corneal inflammation

MU School of Medicine researchers find link between varicella zoster virus vaccine and corneal inflammation

In use for more than 20 years, the varicella zoster virus vaccine for chickenpox and shingles is considered an essential medicine by the World Health Organization. However, researchers from the University of Missouri School of Medicine have found, in rare instances, a link between the vaccine and corneal inflammation. [More]
Asthma in childhood may increase risk of shingles

Asthma in childhood may increase risk of shingles

Nearly 1 million incidences of herpes zoster, which is also known as shingles, occur every year in the U.S., with an estimated one-third of all adults affected by age 80. Despite its prevalence, particularly between ages 50 and 59, it is still unclear why some individuals will develop shingles, and others will not. [More]
Shingles vaccine can help protect elderly patients with end-stage renal disease

Shingles vaccine can help protect elderly patients with end-stage renal disease

Elderly patients with end-stage renal disease (ESRD) who received the shingles vaccine were half as likely to develop shingles compared to those who were not vaccinated. The new study from Kaiser Permanente, published in Clinical Infectious Diseases, also found the best protection against shingles was achieved when patients received the vaccination shortly after beginning dialysis. [More]
Nucala (mepolizumab) approved for treatment of asthma patients

Nucala (mepolizumab) approved for treatment of asthma patients

The U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older. Nucala is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. [More]
ACP awarded $1,002,884 Cooperative Agreement to increase adult immunization rates in US

ACP awarded $1,002,884 Cooperative Agreement to increase adult immunization rates in US

The American College of Physicians (ACP) was awarded a $1,002,884 Cooperative Agreement from the Centers for Disease Control and Prevention (CDC) to increase immunization rates in the United States. [More]
NanoViricides speeds up HerpeCide drug development program

NanoViricides speeds up HerpeCide drug development program

NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, reports that it is accelerating its HerpeCide drug development program. [More]
Study: Chickenpox vaccination increases incidence of shingles in younger adults

Study: Chickenpox vaccination increases incidence of shingles in younger adults

Vaccinating one-year-olds against chickenpox could temporarily nearly double the incidence of shingles in the wider population, but in younger adults than previously thought. [More]
First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the first patient has been enrolled in the Company's pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN). [More]
New white paper provides overview of factors that drive vaccination underutilization in older adults

New white paper provides overview of factors that drive vaccination underutilization in older adults

Today the nonprofit Alliance for Aging Research released a white paper, Our Best Shot: Expanding Prevention through Vaccination in Older Adults, that provides a comprehensive overview of the factors that drive vaccination underutilization in seniors and offers recommendations on how industry, government, and health care experts can improve patient compliance. [More]
UC Davis scientists identify significant driver of neuropathic pain

UC Davis scientists identify significant driver of neuropathic pain

Scientists at the University of California, Davis, have identified a key mechanism in neuropathic pain. The discovery could eventually benefit millions of patients with chronic pain from trauma, diabetes, shingles, multiple sclerosis or other conditions that cause nerve damage. [More]
Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals, Inc., a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments. [More]
Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has engaged the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments using ContraVir's hepatitis B program, CMX157. [More]
New approach to vaccine development is 97 per cent efficacious and  could eliminate shingles

New approach to vaccine development is 97 per cent efficacious and could eliminate shingles

A new vaccine has proven almost completely effective in preventing shingles (disease medical name: herpes zoster), an extremely painful nerve infection which affects a third of Australians; most over the age of 50... [More]
New compound offers longer lasting painkilling effects

New compound offers longer lasting painkilling effects

Medications have long been used to treat pain caused by injury or chronic conditions. Unfortunately, most are short-term fixes or cause side effects that limit their use. Researchers at the University of Missouri have discovered a new compound that offers longer lasting painkilling effects, and shows promise as an alternative to current anesthetics. [More]
Advertisement